Cite
MLA Citation
Philippe Saiag et al.. “Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.” European journal of cancer, vol. 154, 2021, pp. 57–65. http://access.bl.uk/ark:/81055/vdc_100139915950.0x00003b